Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

Abstract Purpose: The aim of this study was to explore the prognostic value of total metabolic tumor volume (TMTV) at baseline 18F-FDG PET/CT in patients diagnosed with peripheral T-cell lymphoma (PTCL).Materials and methods: Eighty-four PTCL patients who underwent baseline 18F-FDG PET/CT between March 2009 and January 2019 and did not receive treatment were enrolled in this retrospective study. The FDG-avid lesions in each patient were segmented using semiautomated software to calculate the maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG) values using the boundaries of voxels presenting with the 41% SUVmax threshold method. Progression-free survival (PFS) and overall survival (OS) were used as end points to evaluate patient prognosis. The log-rank test and Cox regression analyses were used to evaluate PFS and OS.Results: ROC curve analysis indicated an ideal TMTV cut-off value of 228.8 cm3. During the 4-131month (29.2±28.5 months) follow-up period, high TMTV was significantly associated with worse PFS and OS. TMTV and the international peripheral T-cell lymphoma project score (IPTCLP) were independent predictors of PFS and OS with multivariate analysis. The combination of TMTV and the IPTCLP may provide significantly better risk substratification in PFS and OS of PTCL patients.Conclusions: Both TMTV and IPTCLP are independent predictors of PTCL patient survival outcomes. Moreover, the combination of TMTV and IPTCLP improved patient risk stratification and may contribute to personalized therapeutic regimens.

Download Full-text

Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

EJNMMI Research ◽

10.1186/s13550-020-00698-y ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Chong Jiang ◽

Yue Teng ◽

Jieyu Chen ◽

Zhen Wang ◽

Zhengyang Zhou ◽

...

Keyword(s):

T Cell ◽

Fdg Pet ◽

Tumor Volume ◽

Cell Lymphoma ◽

Standardized Uptake Value ◽

Metabolic Tumor Volume ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Pet Ct ◽

Fdg Pet Ct

Abstract Purpose The aim of this study was to explore the prognostic value of total metabolic tumor volume (TMTV) at baseline 18F-FDG PET/CT in patients diagnosed with peripheral T-cell lymphoma (PTCL). Materials and methods Eighty-four newly diagnosed PTCL patients who underwent baseline 18F-FDG PET/CT prior to treatment between March 2009 and January 2019 were enrolled in this retrospective study. The FDG-avid lesions in each patient were segmented using semiautomated software to calculate the maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG) values using the boundaries of voxels presenting with the 41% SUVmax threshold method. Progression-free survival (PFS) and overall survival (OS) were used as end points to evaluate patient prognosis. The log-rank test and Cox regression analyses were used to evaluate PFS and OS. Results ROC curve analysis indicated an ideal TMTV cut-off value of 228.8 cm3. During the 4–131 months (29.2 ± 28.5 months) follow-up period, high TMTV was significantly associated with worse PFS and OS. TMTV and the international peripheral T-cell lymphoma project score (IPTCLP) were independent predictors of PFS and OS with multivariate analysis. The combination of TMTV and the IPTCLP may provide significantly better risk substratification in PFS and OS of PTCL patients. Conclusions Both TMTV and IPTCLP are independent predictors of PTCL patient survival outcomes. Moreover, the combination of TMTV and IPTCLP improved patient risk stratification and may contribute to personalized therapeutic regimens.

Download Full-text

Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

10.21203/rs.3.rs-38884/v3 ◽

2020 ◽

Author(s):

Chong Jiang ◽

Yue Teng ◽

Jieyu Chen ◽

Zhen Wang ◽

Zhengyang Zhou ◽

...

Keyword(s):

T Cell ◽

Fdg Pet ◽

Tumor Volume ◽

Cell Lymphoma ◽

Standardized Uptake Value ◽

Metabolic Tumor Volume ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Pet Ct ◽

Fdg Pet Ct

Abstract Purpose: The aim of this study was to explore the prognostic value of total metabolic tumor volume (TMTV) at baseline 18F-FDG PET/CT in patients diagnosed with peripheral T-cell lymphoma (PTCL).Materials and methods: Eighty-four newly diagnosed PTCL patients who underwent baseline 18F-FDG PET/CT prior to treatment between March 2009 and January 2019 were enrolled in this retrospective study. The FDG-avid lesions in each patient were segmented using semiautomated software to calculate the maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG) values using the boundaries of voxels presenting with the 41% SUVmax threshold method. Progression-free survival (PFS) and overall survival (OS) were used as end points to evaluate patient prognosis. The log-rank test and Cox regression analyses were used to evaluate PFS and OS.Results: ROC curve analysis indicated an ideal TMTV cut-off value of 228.8 cm3. During the 4-131 month (29.2±28.5 months) follow-up period, high TMTV was significantly associated with worse PFS and OS. TMTV and the international peripheral T-cell lymphoma project score (IPTCLP) were independent predictors of PFS and OS with multivariate analysis. The combination of TMTV and the IPTCLP may provide significantly better risk substratification in PFS and OS of PTCL patients.Conclusions: Both TMTV and IPTCLP are independent predictors of PTCL patient survival outcomes. Moreover, the combination of TMTV and IPTCLP improved patient risk stratification and may contribute to personalized therapeutic regimens.

Download Full-text

Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)

Annals of Oncology ◽

10.1093/annonc/mdw011 ◽

2016 ◽

Vol 27 (4) ◽

pp. 719-724 ◽

Cited By ~ 40

Author(s):

A.S. Cottereau ◽

S. Becker ◽

F. Broussais ◽

O. Casasnovas ◽

S. Kanoun ◽

...

Keyword(s):

T Cell ◽

Fdg Pet ◽

Prognostic Value ◽

Tumor Volume ◽

Cell Lymphoma ◽

Metabolic Tumor Volume ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue

Leukemia & Lymphoma ◽

10.1080/10428194.2017.1300891 ◽

2017 ◽

Vol 58 (10) ◽

pp. 2342-2348 ◽

Cited By ~ 3

Author(s):

Anthony Q. Pham ◽

Stephen M. Broski ◽

Thomas M. Habermann ◽

Dragan Jevremovic ◽

Gregory A. Wiseman ◽

...

Keyword(s):

Bone Marrow ◽

T Cell ◽

Fdg Pet ◽

Cell Lymphoma ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis

American Journal of Otolaryngology ◽

10.1016/j.amjoto.2017.10.009 ◽

2018 ◽

Vol 39 (1) ◽

pp. 1-5 ◽

Cited By ~ 10

Author(s):

Kyoungjune Pak ◽

Bum Soo Kim ◽

Keunyoung Kim ◽

In Joo Kim ◽

Sungmin Jun ◽

...

Keyword(s):

T Cell ◽

Retrospective Analysis ◽

Fdg Pet ◽

Cell Lymphoma ◽

Prognostic Significance ◽

Standardized Uptake Value ◽

T Cell Lymphoma ◽

Nasal Type ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

The Role of Pre-Treatment and Mid-Treatment 18F-FDG PET/CT Imaging in Evaluating Prognosis of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS)

10.21203/rs.3.rs-142898/v1 ◽

2021 ◽

Author(s):

Yafei Zhang ◽

Guangfa Wang ◽

Xin Zhao ◽

Yongxian Hu ◽

Elaine Tan Su Yin ◽

...

Keyword(s):

T Cell ◽

Fdg Pet ◽

Cell Lymphoma ◽

Ct Scanning ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Not Otherwise Specified ◽

Pet Ct ◽

Pre Treatment ◽

Fdg Pet Ct

Abstract Background These are limited data on pretreatment evaluation and prognosis assessments of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS). We aimed to determine the prognostic values of pre-treatment and mid-treatment total metabolic tumor volume (MTV), total lesion glycolysis (TLG), and Deauville 5-Point Scale (D-5PS) in accessing the prognosis of PTCL-NOS.Methods A retrospective analysis was conducted in 31 patients with pathologically diagnosed PTCL-NOS. These patients have undergone positron emission tomography-computed tomography (PET-CT) scanning before and during chemotherapy. The follow-ups were done to investigate the 2-year progression-free survival (PFS) and Overall Survival (OS) of these patients. During 18F-fluorodeoxyglucose (18F-FDG) PET/CT scans, the MTV and TLG were recorded. Meanwhile, ∆MTV and ∆TLG were calculated. On the other hand, the mid-chemotherapy assessment and staging of these 31 patients were done by utilizing D-5PS. Subsequently, based on the D-5PS scores obtained, these patients were grouped into two categories: a group of patients with a score of <4 and another group with ≥4. For these two groups of patients, the survival analysis was done by Kaplan–Meier analysis and a multivariate COX regression model. Moreover, Pearson's chi-square test (χ2 test) and Spearman rank correlation coefficient were used to comparing the collected data, respectively.Results During the two-year follow-up period, 15 out of the 31 patients experienced disease progression. The optimal threshold values for both baseline MTV and TLG were 158.16 cm 3 and 677.40.Additionally, the difference in 2-year PFS between the progressive and non-progressive groups was statistically significant (χ2=8.193, P=0.004<0.05; χ2=8.872, P=0.003<0.05), significant between-group difference was detected for MTV and for TLG (χ2=6.494, P=0.011<0.05; χ2=4.687, P=0.03<0.05). When these patients were classified into two groups according to the mid-chemotherapy Deauville score of<4 and ≥4, the statistical difference of 2-year PFS between these two groups was significant, too (χ2=14.966, P=0.001<0.05), but there is no significant between-group difference in OS (χ2=3.337, P=0.068<0.05). COX analysis revealed that D-5PS are the independent factors influencing PFS, while MTV is the independent influencing factor of OS.Conclusion In conclusion, the baseline MTV obtained by PET-CT scanning, and D-5PS are crucial prognostic factors in evaluating the prognosis of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS).

Download Full-text

The Role of An Early Interim 18 F-FDG PET/CT for Prediction of Outcomes of Patients with Peripheral T Cell Lymphoma

Blood ◽

10.1182/blood.v112.11.5272.5272 ◽

2008 ◽

Vol 112 (11) ◽

pp. 5272-5272

Author(s):

Yoon Hee Choi ◽

Byung Woog Kang ◽

Hyun Soo Hong ◽

Chul Kim ◽

Geundoo Jang ◽

...

Keyword(s):

T Cell ◽

Fdg Pet ◽

Cell Lymphoma ◽

Initial Therapy ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Positive Group ◽

Pet Ct ◽

Fdg Pet Ct

Abstract Background Recent studies have demonstrated that positron emission tomography (PET) performed after one to four cycles of multiagent chemotherapy predicts therapeutic outcome in lymphomas which are mainly diffuse large B cell lymphoma and Hodgkin’s lymphoma. However, interim 2-[18F] fluoro-2-deoxy-D-glucose (FDG) PET/CT has not yet been discussed in peripheral T cell lymphoma. In this study, we investigated the role of an interim 18 F-FDG PET/CT for the prediction of the progression free survival (PFS) and overall survival (OS) in peripheral T cell lymphoma. Patients and methods We retrospectively analyzed the medical records of thirty-three patients with newly diagnosed, initially FDG-avid peripheral T cell lymphoma between 2004 and 2007 (median age of 44 years, 18 peripheral T cell lymphoma, unspecified, 9 anaplastic large cell lymphoma, 6 angioimmunoblastic T cell lymphoma) who underwent 18F-FDG PET/CT after one to four cycles of chemotherapy (interim scan). The maximal response to initial therapy was evaluated using conventional methods. Interim FDG-PET/CT results were correlated to the PFS and OS using Kaplan-Meier survival analysis. Cox regression analyses were performed for independence of prognostic factors. Results The median follow up was 23 months (range, 2–52 months). In the initial therapy, 25 patients achieved CR, 5 patients showed progress and 3 patients died. Interim FDG-PET/CT was negative in 17 patients, positive in 9, and 7 patients showed minimal residual uptake (MRU). The CR rate of initial therapy was 100%, 85% (6/7) and 22% (2/9) in the FDG negative, MRU and positive group, respectively. The estimated 2 year PFS was 88.2% for the negative group, 38.3% for the MRU group, and 0% (median survival of 5.6 months) for the positive group. The log rank test showed strong associations between interim FDG-PET/CT results and PFS (P =0.001) and OS (P <0.001). Also, univariate and multivariate analyses showed that the interim FDG-PET/CT was the only independent factor to predict outcomes among known prognostic factors such as age, elevated lactate dehydrogenase, the number of extranodal disease, stage, performance status (p=0.007). Conclusion Interim FDG PET/CT is an excellent and independent predictor of outcomes of patients with peripheral T cell lymphoma and is suggested to be a useful tool to modify the therapy.

Download Full-text